Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04189055|
Recruitment Status : Recruiting
First Posted : December 6, 2019
Last Update Posted : August 26, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.
Patients will be included in cohort #1 or cohort #2. The inclusion in cohort #2 will start when the results of the cohort #1 are available.
Patient will receive either cetuximab alone (cohort #1) or cetuximab with irinotecan (cohort #2).
|Condition or disease||Intervention/treatment||Phase|
|Cancer Colorectal||Drug: Cetuximab Drug: Irinotecan||Phase 2|
Background - Rationale
KRAS and NRAS mutations are present in roughly 50% of patients with advanced colorectal cancer and predict failure of anti-EGFR mabs therapies, thus genotyping colorectal cancer (CRC) is mandatory for personalized treatments.
Research has been selectively concentrated on the emergence of resistant clones in the blood of patients with wild-type (WT) RAS CRC as biomarker of anti-EGFR therapy resistance.
It has been suggested that patients with metastatic CRC harboring mutated primary tumors, thus not candidate to EGFR inhibitors, frequently have WT RAS circulating tumor cells in blood. Preliminary data suggest that patients with mutant KRAS colon cancer can frequently (50%) switch to a prevalent WT KRAS disease in course of treatment with anti-angiogenic drugs.
In patients with RAS wild-type colorectal cancer who previously received standard therapies, anti-EGFR mabs achieve a response rate of 20% as monotherapy and 30-40% in combination with irinotecan.
The aim of this study is to evaluate the efficacy of cetuximab in patients with pretreated neo wild-type colorectal cancer using liquid biopsies for RAS molecular assessment
• To evaluate the response rate using RECIST 1.1
- To evaluate progression-free survival (PFS), overall survival (OS)
- To evaluate disease control rate (DCR)
- To evaluate safety
- Frequency of neo wild-type tumors
- Frequency of RAS and BRAF neomutations during treatment
Study Design Prospective multicentric single-arm open-label phase II study in to 2 successive patient cohorts (cohort #1 followed by cohort #2).
Molecular screening using Idylla™ (Biocartis) ctKRAS and ctNRAS/BRAF Mutation Assays.
Cohort #1: Patients will be treated with cetuximab monotherapy (cetuximab 500mg/m² IV, day 1).
Cohort #2: Patients will be treated with cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
In both cohorts, treatment will be given intravenously every 14 days (q2w) until disease progression or limiting toxicity. Tumor evaluations will be done with CT-scan (or MRI) every 8 weeks using RECIST v1.1.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. A Proof-of-concept Study|
|Actual Study Start Date :||January 7, 2020|
|Estimated Primary Completion Date :||April 2023|
|Estimated Study Completion Date :||July 2023|
Experimental: Cohort #1
Cetuximab monotherapy (500mg/m² IV, day 1)
Cetuximab 500mg/m² IV, day 1
Other Name: Erbitux
Experimental: Cohort #2
Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).
Cetuximab 500mg/m² IV, day 1
Other Name: Erbitux
Irinotecan 180mg/m² IV, day 1
Other Name: Campto
- response rate [ Time Frame: 4 months ]Tumor measurements will be obtained at baseline and every 8 weeks following treatment initiation. At the investigator's discretion, tumor assessments may be repeated at any time if progressive disease is suspected. Tumor response and progression will be assessed by the Investigator using RECIST v1.1.
- Overall survival [ Time Frame: time interval from inclusion to the date of death from any cause. Assessed up to 12 months after the beginning of the study ]OS is defined as the time interval from the date of inclusion to the date of death from any cause. Alive patients will be censored at the last date known to be alive, either during study treatment period or during follow-up period.
- Progression-free survival [ Time Frame: the time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 12 months after the beginning of the study ]PFS is defined as the time interval from the date of inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Alive patients without progression will be censored at the last tumor assessment, either during study treatment period or during follow-up period.
- Disease Control rate [ Time Frame: from baseline until end of treatment, assessed up to 12 months after the beginning of the study ]Disease control rate (DCR) is defined as the percentage of patients achieving CR, PR, or stable disease (SD).
- Tolerance [ Time Frame: Assessed from study entry to 1 month after last study drug administration, assessed up to 12 months after the beginning of the study ]Frequency of adverse events using NCI-CTCAE v5.0
- Tumor biomarkers [ Time Frame: Assessed from study entry to end of study treatment, assessed up to 12 months after the beginning of the study ]Tumor biomarkers will be tested : mismatch repair system (pMMR vs dMMR), HER1 (EGFR expression), HER2 expression, amphiregulin (AREG) and HER1 (EGFR GCN, cut-off 4.0), HER2, PI3KCA, PTEN, IRS2,
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Provision of signed and dated informed consent and stated willingness to comply with all study procedures and availability for the duration of the study,
- Male or female subjects, ≥18 years of age,
- ECOG performance status (ECOG PS, Appendix 15.1) ≤2,
- Unresectable metastatic RAS mutant (either KRAS or NRAS tumor gene mutation) colorectal cancer,
- At least one (≥1) measurable and/or evaluable liver metastasis,
- Prior therapy (resistant or intolerant) with fluoropyrimidines, oxaliplatin, irinotecan and antiangiogenic agent (ie, bevacizumab and/or aflibercept),
Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:
Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin ≥9g/dL Adequate renal function: serum creatinine clearance (MDRD) ≥ 50 mL/min/1,73 m2 Adequate liver function: serum bilirubin ≤1.5x upper normal limit (ULN), alkaline phosphatase <5xULN, AST and ALT ≤5xULN, Adequate serum electrolyte levels (magnesium, potassium, calcium) prior to initiation of study treatment,
- Negative pregnancy test within 7 days prior to initiation of the study drug for female patients of childbearing potential,
- Effective contraception for both male and female subjects if the risk of conception exists
- Registration in a national health care system.
- Known allergy or hypersensitivity reactions to any study drug,
- Women who are pregnant or breastfeeding,
- Inability to comply with study and follow-up procedures as judged by the Investigator,
- Patient with BRAF mutant colorectal cancer
- History of interstitial lung disease
- Treatment with strong CYP3A4-enzyme inducers such as anticonvulsants (phenytoin, phenobarbital or carbamazepine), rifampin, rifabutin and St. John's wort for patients of cohort #2
- Treatment with strong CYP3A4-enzyme inhibitors (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) for patients of cohort #2
- Treatment with strong UGT1A inhibitors (e.g. atazanavir, gemfibrozil, indinavir) for patients of cohort # 2
- Patients of cohort #2 with known UGT1A deficiency
- Uncontrolled illness, including but not limited to ongoing bacterial, viral or fungal infection requiring systemic therapy, metabolic dysfunction, physical examination/ clinical laboratory finding that leads to a reasonable suspicion of a disease/condition that contraindicates the use of any of investigational drugs that may affect the interpretation of the results, or that may render the subject at high risk of treatment complications.
- Patient with current intestinal obstruction or history of chronic inflammatory bowel disease
- Subjects under guardianship, curatorship or judicial protection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04189055
|Contact: Benoist CHIBAUDEL, MD||0147595965 ext email@example.com|
|Franco-British Hospital - GCS IHFB Cognacq-Jay||Recruiting|
|Levallois-Perret, France, 92300|
|Principal Investigator:||Benoist CHIBAUDEL, MD||Franco-British Hospital - GCS IHFB Cognacq-Jay|
|Responsible Party:||GCS IHFB Cognacq-Jay|
|Other Study ID Numbers:||
|First Posted:||December 6, 2019 Key Record Dates|
|Last Update Posted:||August 26, 2021|
|Last Verified:||February 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Topoisomerase I Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological